Citi analyst Joanne Wuensch lowered the firm’s price target on Sight Sciences to $1.80 from $4 and keeps a Neutral rating on the shares after the company reported Q4 results and withdrew 2023 guidance. The firm updated its model to incorporate increased reimbursement uncertainty, with the model now assuming the other four CMS MACs will follow WPS and find Omni investigational.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
- Disaster for Sight Services (NASDAQ:SGHT): Shares Fall on Medicare Concerns
- Piper says WPS update ‘massive blow’ to Sight Sciences, good news for Glaukos
- Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
- Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
